TR2021022265A2 - Acetylcholinesterase Inhibitory Activity of Salt Samples of Prulifloxacin Molecule, Prulifloxacin Isomer Molecule Forms, or Their Pharmaceutically Accepted Prulifloxacin Isomer Molecule Forms - Google Patents

Abstract

The present invention can be used in the treatment of various diseases or disorders caused by AChE, containing prulifloxacin or prulifloxacin derivatives with acetylcholinesterase (AChE) inhibitory property, or natural or synthetic forms of their pharmaceutically acceptable salts, as pharmaceutical composition and functional food and carriers, and AChE inhibitor molecule.

Description

DESCRIPTION Prulifloxacin Molecule, Prulifloxacin Isomer Molecular Forms or Thereof Salt of Pharmaceutically Acceptable Prulifloxacin Isomer Molecule Forms Acetylcholinesterase Inhibitor Activity of Samples Technical Field to which the Invention Relates: The presented invention contains prulifloxacin, prulifloxacin derivatives and their pharmaceutical preparations. composition and functional food and pharmaceutically acceptable salts of acetylcholinesterase It is related to (AChE) Inhibitor properties.

Known Status of the Technique: Acetylcholine, an alkaloid, was the first neurotransmitter identified. Located in the central nervous system In addition to being a chemical-transmitter that receives It is located in the parasympathetic nervous system (including humans). For the first time in 1914, the British Acetylcholine, defined by scientist Henry Hallet Dale, is the compound of choline with acetic acid. is the ester. In 1921, frog hearts were discovered by Australian scientist Otto Lewi. This discovery, which was confirmed as a neurotransmitter as a result of his experiments on It brought scientists the Nobel Prize in 1936.

In certain neurons, acetylcholine is separated from choline and acetyl-CoA by the enzyme acetyl esterase. is synthesized. After completing its task by being released into the synaptic space Acetylcholine is converted into acetate, a salt of choline and acetic acid, with the help of the enzyme acetylcholinesterase. It is turned and destroyed. Additionally, acetylcholinesterase, called AChE, has hydrolytic activity. The activity of parasympathetic neurons, especially by forming the choline and acetate group, increases the activity of parasympathetic neurons. It is an enzyme that enables the degradation of the neurotransmitter acetylcholine (ACh).

To perform its function, AChE is produced in the membrane of the endoplasmic reticulum. is transported to the cell membrane. AChE is mainly produced in and around cholinergic neurons, especially found at the attachment points of the muscles, as well as in the plasma, liver and other tissues It is an important enzyme.

Generally, acetylcholine is secreted from the membrane at the axon tip towards the synaptic gap and transfers action potential by binding the post-synaptic neuron receptor It is a neurotransmitter. After the stimulus is carried to the neuron, it is degraded to choline and acetate by AChE. occurs, which is then used to synthesize new acetylcholine molecules again through reabsorption. is carried back to the nerve endings.

Acetylcholine research has shown that various physical and mental diseases/disorders, acetylcholine mechanism and an abnormal concentration of synthesized acetylcholine. It has been revealed that there is a significant relationship between the decrease in the level of

Acetylcholine is currently implicated in the pathogenesis of Alzheimer's and Parkinson's diseases. It is known that it has an important place in the mechanism. Also known as dementia Alzheimer's disease (AD) is typically the most well-known acetylcholine-related disorder.

The most important symptoms of Alzheimer's disease are memory loss, speech impairment and is dementia. To date, various hypotheses have emerged for the mechanism and pathogenesis of the disease. Atilsa is still not fully known.

In addition, the central nervous systems of patients with Alzheimer's disease generally cannot be repaired, and cholinergic neurons in particular cannot be repaired. With this, Patients suffering from Alzheimer's disease due to failure of cholinergic neurons to repair Cognitive achievement is reported to be deeply related to decline in memory and learning. has been done.

Restoration efforts of the cholinergic neuron associated with AD are suggested by the cholinergic hypothesis. is being driven. According to this hypothesis, successful results can be achieved in the treatment of AD disease. towards the restoration of actively damaged cholinergic neurons. The necessity of doing this is stated.

ACh, a cholinergic neurotransmitter, is used to heal irreparable cholinergic neurons. use of the precursor molecule, use of cholinergic receptor agonists or AChE A method to balance the concentration of ACh in the synapse with its inhibitors is implemented. However, since cholinergic receptor agonists are degraded in ViVO, AChE inhibitors are used.

It inhibits the enzyme acetylcholinesterase, as it has a deep connection with acetylcholine deficiency. Some drugs are used to treat diseases such as Alzheimer's disease.

In myasthenia gravis, which is a neuromuscular disease, the body responds to acetylcholine receptors. It is known that it prevents a proper acetylcholine signal transfer by producing antibodies against it. This In the treatment of the disorder, drugs such as Physostigmine, which inhibit the acetylcholinesterase enzyme, are used. is used. Additionally, acetylcholine is a rapid stimulation of the pupil during cataract surgeries. It is used to undergo constriction (shrinkage).

Therapeutic drugs for Alzheimer's that have been approved by the American Food and Drug Administration (FADl) AChE inhibitors used as tacrine (THA, Cognex®), donepezil (Acricept®) and rivastigmaine (Exel0n®), among which are obtained from natural products compounds are galanthamine (Galanthus nivalis), huperzine A (Huperzia serrata) and others.

AChE keeps the concentration of ACh constant by protecting it from ACh degradation Inhibitors have the effect of improving cognitive (judgment, perception) function. However. AChE Inhibitors have many known properties such as hepatotoxicity, short half-life, low biocompatibility. It has a problem. Therefore, many studies have focused on the development of new AChE inhibitors. It is done on.

At the same time, in other pathological studies related to the choline nervous system, gastrointestinal movement is controlled by nerve impulses and acetylcholine increases stomach function has been reported. Therefore, neostigmine, a type of AChE inhibitor, increases abdominal distension due to postoperative ileus (intestinal obstruction after surgery) or In the treatment of dysuria (urinary difficulty) caused by bladder detrusor insufficiency is used.

Additionally, the autoimmune neuromuscular disease myasthenia gravis is associated with post-synaptic neuromuscular disease. neurotransmitter due to the disruption of acetylcholine receptors at their junction points. The simulative (stimulating) effect of acetylcholine is impaired. acetyl such as mestinon or neostigmine It is treated with choline inhibitors. Mestinon is often used in the treatment of myasthenia gravis. is used. Thus, acetylcholine remains on the receptors in the muscle cells. Acetylcholine concentration is increased. Although treatment in a short time seems to be an advantage, Depending on the dose, side effects such as vomiting and abdominal pain may occur. myasthenia Newly developed acetylcholine esterase inhibitors are nicotinic or muscarinic inhibitors in the treatment of gravis. They do not show selectivity for acetylcholine receptors, so muscarinic acetylcholine Undesirable effects occur with stimulation of the receptor. Moreover, their absorption rate is very high. are low and treatment intervals are narrow due to their partial effectiveness.

Glauooma is a progressive, irreversible loss of vision due to intraocular pressure. It is a disease in which the optic nerves are damaged. In this context, according to the information available, acetylcholine Esterase inhibitors ensure the reabsorption of aqueous fluid. Thus intraocular pressure is reduced. However, the issue that needs particular attention is Glaucoma. Risk of catarrh formation if treatment with AChE inhibitors continues for more than 6 months is occurring.

Treatment or treatment of various diseases or disorders associated with low ACh concentration application of precursor ACh molecules to facilitate ACh synthesis in It is recommended as an alternative method. However, without entering the blood brain barrier AChE with ACh hydrolytic activity, such as Tacrin, due to their short-time interactions Medicines are mostly used in treatment.

As mentioned above, currently developed and commercially available AChE Hepatopathy, gastrointestinal distribution (abdominal pain or vomiting), muscle pain It has many side effects such as etc.

Pruiroxacin is the oldest synthetic antibiotic of the fluoroquinolone drug class.

Pmlifloxacin is a pioneer drug. In respiratory and urinary tract infections in Italy, in Japan It has been approved to treat diarrheal infections without complications.

As a result of large-scale calculations, various forms of prulifloxacin have higher levels of acetylcholine. It reduces the activity of the esterase enzyme and even has this effect today as an AChE inhibitor. It has been observed that it has a much stronger effect than the drugs used.

Therefore, the presented invention covers various problems related to the abnormal decrease in aCetylcholine concentration. It proposes a molecule that can be used in the treatment of diseases and disorders. this molecule It is synthetically obtained with high aceticcholine estrease inhibition activity. It relates to the prulifloxacin molecule in various forms that can be obtained.

Technical Problems That the Invention Aims to Solve: The aim of the present invention is to provide prulifloxacin with AChE inhibition activity. determination of the molecule.

Another aim of the present invention is to use various compounds with AChE inhibition activity. Determination of prulifloxacin isomer molecular forms.

Another object of the present invention is to use the prulifloxacin molecule or various prulifloxacin isomeric forms of molecules or have the ability to inhibit AChE activity It is the preparation of pharmaceutically acceptable salts.

Another purpose of the presented invention is to treat the weakness of the smooth muscles of the gastrointestinal region. (myasthenia), bladder, in the treatment of neurodegenerative diseases or glaucoma or providing pharmaceutical composition or pharmaceutically acceptable Salts of the prulifloxacin molecule or various prulifloxacin isomer molecule forms is to be determined.

Another purpose of the presented invention is to treat the weakness of the smooth muscles of the gastrointestinal region. (myasthenia), bladder, in the treatment of neurodegenerative diseases or glaucoma or providing pharmaceutical composition or pharmaceutically acceptable Salts of the prulifloxacin molecule or various prulifloxacin isomer molecule forms is to use.

Another purpose of the presented invention is to treat the weakness of the smooth muscles of the gastrointestinal region. (myasthenia), bladder, in the treatment of neurodegenerative diseases or glaucoma or providing pharmaceutical composition or pharmaceutically acceptable Salts of the prulifloxacin molecule or various prulifloxacin isomer molecule forms is to use.

Pruiifloxacin molecule or various prulifloxacin isomer molecule forms or pharmaceutical Salts considered to be potent acetylcholine esterase inhibitors inhibit AChE activity. It is an inhibitor. Thus, by being included in the pharmaceutical composition or carrier, weakness of the smooth muscles of the gastrointestinal tract (myasthenia), bladder, neurodegenerative Pharmaceutical composition for the treatment or prevention of diseases or glaucoma providing or using the pharmaceutically acceptable prulifloxacin molecule or various It is the use of salts of prulifloxacin isomer molecular forms.

Description of the invention: Unless otherwise defined, technical and scientific terms used herein are commonly used to describe the invention. The same understanding as is generally understood by a person of ordinary skill in the technical field in which it is applied. has.

In the present invention, the prulifloxacin molecule or various prulifloxacin isomer molecules AChE forms or salts of various prulifloxacin isomer molecular forms It is stated that it has inhibitory activity.

The presented invention is based on the hydrolytic activity of acetylcholine esterase, also known as AChE. It degrades the neurotransmitter acetylcholine, forming choline and acetate groups with the help of acetyl It is related to an enzyme that can cause profound changes in choline concentration. ischemic Neurodegenerative diseases such as brain disease, myasthenia gravis, memory defects, alcohol addiction diseases, myasthenas (weakening) of gastrointestinal smooth muscle or glaucoma or urinary tract various diseases associated with abnormal decrease in acetylcholine concentration, such as in the bladder It can be used to treat diseases or disorders.

Some prulifloxacin isomeric molecular forms or their pharmaceutically acceptable Salts of prulifloxacin isomer molecular forms have higher potential AChE inhibitors. They may have the feature of showing activity.

In the present invention, the prulifloxacin molecule or various prulifloxacin isomer molecules Ischemic brain neurodegenerative diseases such as disease, myasthenia gravis, memory defects, alcohol addiction diseases, myasthenas (weakening) of gastrointestinal smooth muscle or glaucoma or urinary tract various diseases associated with abnormal decrease in acetylcholine concentration, such as in the bladder It can be used to treat diseases or disorders.

Prulifloxacin isomer molecule forms shown in Figure 1 are an antibiotic. In the presented invention, It also includes pharmaceutically acceptable salts of the prulifloxacin inoleculum.

Pharmaceutical salts of prulifloxacin or alkaline salts of prulifloxacin unless otherwise specified. may contain groups or acidic salts. Examples of acidic or basic groups hydroxyl groups, sodium, potassium, calcium, potassium salts and hydrobronide salts, amidogen groups, amino groups p-toluene sulfonate (Tosylate) and methane sulfonate (mesylate) madelate, lactate, tartrate, citrate. succinate, acetate, dihydrogen phosphate, background methods or processes with hydrogen phosphate, phosphate, hydrosulfate groups It can be prepared using .

In addition, the free acid and the acid added salt are pharmaceutically acceptable. It can be used for its soluble salts. Acid-added salt, with a large amount of acid solution soluble compounds, followed by water-soluble compounds such as methanol, ethanol, acetone, or acetonitrile. followed by the precipitation of organic solutions and acidic salts. Compounds with similar molar amounts and acids in alcohol or water, such as glycol monoethyl ether, can be heated and then obtained The resulting mixture can be evaporated or dried, or the precipitated salt can be filtered by suction.

Organic acid or inorganic acid can be used as free acid. Examples of organic acids hydrochloric acid, phosphoric acid, nitric acid or tartaric acid, examples of inorganic acids are methane sulfonic acid, p-toluene, sulfonic acid, acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, fumaric acid, mandelic acid, propionic acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorpic acid, carbonic acid, vanillic acid, hydroiodic acid and the like.

The formation of pharmaceutical metal salts with base can be used for the present invention. alkaline or alkaline earth metal salts, compound in alkaline metal hydroxide or alkaline earth metal dissolving in salts, filtering and evaporating compounds from insoluble salts It can be obtained by traditional methods by filtering and drying.

Sodium potassium calcium salts may be preferred and are formed by the reaction of sodium with potassium. prepared silver salts] or calcium salts with suitable silver salts (e.g. silver nitrate)] preferable.

The present invention relates to the decrease in ACh concentration by AChE activity. such as ischemic brain disease, myasthenia gravis, memory defects, alcohol habit neurodegenerative diseases, myasthenia (weakening) of gastrointestinal smooth muscle, or Abnormally decreased acetylcholine concentration, such as glaucoma or urinary tract (bladder) in the treatment of or protection against diseases/disorders related to Provides pharmaceutical compound.

The pharmaceutical composition of the present invention may be based on pharmaceutically acceptable carriers and/or substance added to medicines to be prepared to give them a suitable shape or a pleasant taste It can form formulations with (excipient). Examples of suitable carriers and excipients lactose, dextrose, sorbitol, mannitol, xylitol, maltitol, starch, acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxy benzonate, propylhydroxybenzolate, talc, magnesium cetarate and mineral oil.

Exceptionally, the compound of the invention may be anticoagulant and protective.

The pharmaceutical composition of the presented invention can be used in oral, nebulized, topical (buccal, sublingual, including the dermal and intraocular route), parenteral (subcutaneous, intradermal, intraocular) periodontal, intracerobrospiral, intramuscular, intravascular and intraarticular routes) or Although it is applied transdermally, it is not limited to these methods only.

However, the composition of the present invention cannot be used alone or with an AChE inhibitor background. It can be used together with other drugs. Examples of acetylcholine esterase inhibitors, Aricept (donepezil hydrochloride capsule commercialized by Eisai), Amirine (Nikken), SM- Zifrosilone (Marion Merrel Dow). These acetylcholine inhibitors Brufani et al. (Alzheimer's Schmidt et al. (Alzheimer Disease: From Molecular Biology to Therapy, eds. Becker et al., Patented by.

The presented invention composition is used for ischemic brain disease, myasthenia gravis, memory defects, neurodegenerative diseases such as alcohol dependence, myasthenas of gastrointestinal smooth muscle (weakening) or in the early stages of diseases such as glaucoma or urinary cavity (bladder) It can even be used in the later stages of the disease. can be given, but there is no limit. Again, Ischemic brain disease, myasthenia gravis, memory defects, neurodegenerative diseases such as alcohol dependence, gastrointestinal smooth muscle diseases such as myasthenas (weakening) or glaucoma or urinary tract (bladder) can be used for protection. The presented invention composition can be repeated as many times as necessary. is applicability. For example, daily or 1-12 weeks depending on the clinical need of the patient. in the range, preferably 3-8 weeks, but not depending on these limits, at appropriate intervals or It can be applied according to the daily clinical needs of the patient.

The composition of the presented invention provides the release or rapid release of active ingredients. can be formulated. These formulations are tablet, powder, suspension, emulsion, solution, syrup, aerosol, sterile injectable solution, hard capsule, sterile powder and so on is possible. It is preferable to provide the composition of the presented project in single dose form. is to be done.

The composition of the present invention can be administered in a therapeutically effective amount. therapeutically The effective amount can be expressed as the dose that can treat the disease or disorder.

The composition of the present invention, its therapeutically effective amount, variety of patient symptoms, period of treatment, rate of excretion, route of administration, time of administration, food, individual patient Various factors, including breed, reaction sensitivity, health, weight, age and treatment conditions. defined in the light of factors. The doses given above will cover all treatments. It does not cover. For example, for animals other than humans, the composition of the invention is unique The most preferred is 500-1000 IU/kg. Further, a single dose of the composition of the invention for humans It can be applied regardless of body weight.

On the other hand, the presented invention relates to methods to be used for protection or ischemic brain neurodegenerative diseases such as disease, myasthenia gravis, memory defects, alcohol addiction diseases, myasthenas (weakening) of gastrointestinal smooth muscle or glaucoma or urinary tract various diseases associated with abnormal decrease in acetylcholine concentration, such as in the bladder prulifloxacin molecule or prulifloxacin in the treatment of diseases or disorders isomer molecule forms or the pharmaceutically acceptable prulifloxacin isomer thereof Salts of the molecular forms can be used.

The terms prevention and treatment used herein refer to prevention or protection methods and therapeutic methods. refers to measurements. Thus, the presented invention can treat the sample in need of treatment in the environment. Such as ischemic brain disease, myasthenia gravis, memory defects, alcohol addiction neurodegenerative diseases, myasthenia (weakening) of gastrointestinal smooth muscle, or It can be used to protect against diseases such as glaucoma or urinary tract (bladder). Here The living thing defined as an example means humans, primates and cats in need of treatment. dog, pig, horse dog etc. It includes mammals such as.

Another embodiment is the use of healthy food or food products in which the presented invention can be used for coma. diseases/disorders acetylcholine concentration by acetylcholine esterase activity ischemic brain disease, myasthenia gravis, memory defects, alcoholism associated with a decrease in Neurodegenerative diseases such as addiction, weakening of gastrointestinal smooth muscle (myasthena) or abnormal acetylcholine concentration, such as glaucoma or urinary tract (bladder) in the treatment of diseases/disorders related to the decrease in It is related to the pharmaceutical compound that may be used.

The healthy food of the presented invention is prulifloxacin molecule or prulifloxacin isomer molecule forms or pharmaceutically acceptable prulifloxacin isomer molecules thereof Salts of these forms can be contained alone or with other foods. More, healthy The invention for food can be used according to traditional methods. Ratio of ingredients in food It can be determined depending on the intended use (protection, health or treatment of diseases).

In general, prulifloxacin molecule or prulifloxacin isomer molecule forms or salts of their pharmaceutically acceptable prulifloxacin isomer molecular forms. samples 10% or less, preferably 5% or less, by weight of food or drink can be added for preparation. However, in order to protect health, long-term food intake It may also contain lower amounts of the active ingredient. Besides, the presented invention is not greater than the known amount of active ingredient, unless it produces a harmful effect. can be used.

There is no limit to the variety of healthy foods. Where samples of healthy food can be mixed prulifloxacin molecule or prulifloxacin isomer molecule forms or their pharmaceutical forms Salt samples of prulifloxacin isomer molecular forms, foods, sausages, bread, chocolate, candies, candies, pizza, gummies, ice cream Etc. daily products such as, in various soups, beverages, tea, alcoholic beverages and vitamin composition can be used. The nutrients of the presented invention are those of traditional/commercially sold healthy foods. If the food of the presented invention is healthy drinks, healthy drinks contain various sweetening agents, It may contain natural hydrocarbons or an added component similar to commercial beverages.

Natural hydrocarbons include monosaccharides such as glucose or fructose, maltose and sucrose. in disaccharides, natural sweeteners such as cyclodextrin or dextrin or saccharin or There may be synthetic sweeteners such as aspartame. The ratio of natural hydrocarbons in healthy drinks In addition, the food of the presented invention contains various food additives, vitamins, electrolytes, dyeing agents, protective agents, pectic acid and its salts, alginic acid and its salts, organic acid, preservatives Viscous agents, pH controlling agents, stabilizers, glycerin, alcohol and Carbonizing agents can be used for carbonated products. However, offered The food of the invention is fresh for natural fruit juice, fruit juice drinks and vegetable juice drinks. Fruits and vegetables can be chosen. The proportions of the specified additives are not very critical and are generally It can be selected as one percent of the weight of the food.

Claims (1)

CLAIMS . It is an application based on bringing an effective amount of molecules into contact with cells, and its feature is; The molecule or its isomer molecule forms or its pharmaceutically accepted salts have acetyl choline esterase (AChE) inhibitor (AChEI) activity in their natural or synthetic forms. . The common cause of ischemic brain disease, myasthenia gravis, memory defects, neurodegenerative diseases such as alcohol addiction, Alzheimer's disease, Parkinson's disease, myasthena (weakening) of the gastrointestinal smooth muscle or glaucoma or urinary space (bladder) diseases is related to AChE, and its feature is; The main claim is that the said molecules and molecule forms have AChEI activity that can be used in the treatment of diseases. . The substance specified as a molecule in the claim is the prulifloxacin molecule of the present invention, and its feature is; It has AChEI activity. . The invention presented in the claim is a natural or synthetic form of the prulifloxacin molecule or pharmaceutically acceptable salts of the molecule, and its feature is; The natural or synthetic form of the prulifloxacin molecule or the pharmaceutically acceptable salts of the molecule have AChEI activity. . It is the prulifloxacin molecule and pharmaceutical salts of the molecule presented in the claim, and its properties are; hydroxyl groups, sodium, potassium, calcium, potassium salts and hydrobromide salts, amino groups containing basic groups or acidic salts, p-toluene sulfonate (Tosylate), methane sulfonate (mesylate) madelate, lactate, tartrate, citrate, succinate, acetate, dihydrogen phosphate It has hydrogen phosphate, phosphate and hydrosulfate groups. . The prulifloxacin molecule or its forms in claims 1, 4 or 5 can be used in the treatment of diseases in living creatures, and its feature is; In the treatment of neurodegenerative diseases such as ischemic brain disease, myasthenia gravis, memory defects, alcohol addiction, Alzheimer's disease, Parkinson's disease, myasthena (weakening) of the gastrointestinal smooth muscle or glaucoma or urinary space (bladder) diseases, to reduce the effects of the disease or to treat the disorders caused by the disease. The effective amount (dose) of prulifloxacin molecules or pharmaceutically acceptable salts that can be used has AChEI activity. . The cause of the diseases specified in claim 2 in living beings is related to AChE, and its feature is; The prulifloxacin molecule and its forms as in claims 3, 4 or 5 have a therapeutic effect by contacting them with the help of a technique in an effective amount as specified in claim 1. Mammals specified as living creatures in claim 7; human, dog, cat, cow, ox, buffalo, sheep, lamb, ram, goat, poultry; It is in contact with chickens, budgies, pigeons, parrots and turkeys and the therapeutic molecules of the diseases specified in Claim 2, and its feature is; The invention presented in Claim 3 is that the prulifloxacin molecule or its forms specified in Claim 4 or 5 has a therapeutic effect as claimed, due to its AChEI effect on living beings. The treatment of the diseases specified in claim 2 is the large in vivo contact of therapeutic molecules and cells, and its feature is; The prulifloxacin inoleculum and its forms as in claims 3, 4 or 5 have the ability to be used as a therapeutic agent. The invention prulifloxacin molecule presented in Claim 3 or the forms specified in Claim 4 or 5 are therapeutic agents for the diseases specified in Claim 2, as stated in Claim 9, and its feature is; AChEI has the ability to be applied in the same formulation in its therapeutic use. The prulifloxacin molecule presented in Claim 3 or the forms specified in Claim 4 or 5 are therapeutic active molecules for the diseases specified in Claim 2 as stated in Claim 9, and its feature is; AChEI has the ability to be applied in different formulations when used as a therapeutic standard. The invention presented in Claim 3 for the treatment of the diseases specified in Claim or for the prevention of diseases is the prulifloxacin molecule or the molecule with AChE activity in the forms specified in Claim 4 or 5, and its feature is; The present invention shown in the pharmaceutical composition has the prulitloxacin molecule or at least one of its forms specified in claim 4 or 5. The invention prulitloxacin molecule presented in Claim 3 or its forms specified in Claim 4 or 5* has AChEl effect in the treatment of the diseases specified in Claim 2 or in the prevention of diseases, and its feature is; It has the feature of being applied as a supplementer (supporter or additive) for therapeutic purposes. In the pharmaceutical composition for the treatment or protection of the diseases specified in Claim 2, at least one of the prulifloxacin molecule, prulifloxacin isomer molecule forms or salt samples of their pharmaceutically acceptable prulifloxacin isomer molecule forms. Its feature is that it has the ability to be used in foods as stated in Claim 13. The prulifloxacin molecule and its forms in Claim 3, 4 or 57 are used together with drugs that have AChEl effect, and its feature is that when used together, the synergistic effect is stronger than when used individually. The invention presented in Claim 3 is present in a composition containing the prulitloxacin molecule or the forms specified in Claim 4 or 5, a pharmaceutically acceptable carrier, excipient or diluent, and its feature is that it has the ability to transport the molecules without deterioration and maintain their properties. The presented invention is the confinement of the prulitloxacin molecule or its forms specified in Claim 4 or 5 using carriers and coatings, and its feature is; It has the ability to be transported in the body of living things and has ACHEI activity. The prulifloxacin molecule and its forms in claims 3, 4 or 5 are important in protecting and transporting ACHEI activity, and its feature is; The substances specified as carriers in l7° or l7° must not have any Iiposomi chitosan, quantum dot, chemical carriers and their nano-micro sized derivatives. The prulifloxacin molecule and its forms in claims 3, 4 or 57 have ACHEI activity and its feature is; The pharmaceutical composition of the molecules used as a therapeutic agent has the ability to be applied orally, nebulized, topically (including buccal, sublingual, dermal and intraocular), parenteral (subcutaneous, intradermal, intraperiodontal, intraceroboral, intramuscular, intravascular and intraarticular) or transdermally. is to have. The invention prulifloxacin molecule presented in Claim 3 or its forms specified in Claim 4 or 5 can be carried within the body as specified in Claim 7 or 19 and used in the treatment of the diseases specified in Claim 2, and its feature is; Therapeutic molecules have the ability to be applied in the form of capsules, dragees, powders and creams.